{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:01:55Z","timestamp":1791291715140,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urology"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1016\/j.urology.2009.02.022","type":"journal-article","created":{"date-parts":[[2009,4,18]],"date-time":"2009-04-18T04:38:34Z","timestamp":1240029514000},"page":"S21-S27","source":"Crossref","is-referenced-by-count":21,"special_numbering":"S","title":["Risk of Developing Prostate Cancer in the Future: Overview of Prognostic Biomarkers"],"prefix":"10.1016","volume":"73","author":[{"given":"Neil E.","family":"Fleshner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Lawrentschuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2009.02.022_bib1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","article-title":"Cancer statistics, 2008","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urology.2009.02.022_bib2","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa074311","article-title":"Quality of life and satisfaction with outcome among prostate-cancer survivors","volume":"358","author":"Sanda","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2009.02.022_bib3","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/cncr.22433","article-title":"Cumulative cost pattern comparison of prostate cancer treatments","volume":"109","author":"Wilson","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2009.02.022_bib4","first-page":"1263","article-title":"Lipid screening to prevent coronary artery disease: a quantitative evaluation of evolving guidelines","volume":"163","author":"Grover","year":"2000","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.urology.2009.02.022_bib5","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.urology.2009.02.022_bib6","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.eururo.2007.11.064","article-title":"Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT Study","volume":"53","author":"Rosario","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2009.02.022_bib7","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.urology.2007.06.1105","article-title":"Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng\/mL","volume":"70","author":"Canby-Hagino","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.urology.2009.02.022_bib8","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1001\/jama.267.16.2215","article-title":"Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease","volume":"267","author":"Carter","year":"1992","journal-title":"JAMA"},{"key":"10.1016\/j.urology.2009.02.022_bib9","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/jnci\/djj131","article-title":"Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial","volume":"98","author":"Thompson","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urology.2009.02.022_bib10","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/jama.273.4.289","article-title":"A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer","volume":"273","author":"Gann","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.urology.2009.02.022_bib11","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0090-4295(01)01304-8","article-title":"Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging","volume":"58","author":"Fang","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.urology.2009.02.022_bib12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.juro.2008.09.012","article-title":"Defining increased future risk for prostate cancer: evidence from a population based screening cohort","volume":"181","author":"Schr\u00f6der","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2009.02.022_bib13","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1111\/j.1464-410X.2008.08214.x","article-title":"Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial","volume":"102","author":"Grubb","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2009.02.022_bib14","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2006.06.9351","article-title":"Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44-50 years","volume":"25","author":"Lilja","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2009.02.022_bib15","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1464-410X.2004.05187.x","article-title":"Prostate cancer screening","volume":"94","author":"Catalona","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2009.02.022_bib16","doi-asserted-by":"crossref","unstructured":"Lilja H, Cronin A, Scardino P, et al. Poster 589: a single PSA predicts prostate cancer up to 30 years subsequently, even in men below age 40. Presented at the Annual Meeting of the American Urological Association, May 17-22, 2008, Orlando, FL.","DOI":"10.1016\/S0022-5347(08)60597-2"},{"key":"10.1016\/j.urology.2009.02.022_bib17","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1002\/ijc.22956","article-title":"The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy","volume":"121","author":"Vickers","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urology.2009.02.022_bib18","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1741-7015-6-6","article-title":"Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study","volume":"6","author":"Ulmert","year":"2008","journal-title":"BMC Med"},{"key":"10.1016\/j.urology.2009.02.022_bib19","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1056\/NEJMoa031918","article-title":"Prevalence of prostate cancer among men with a prostate-specific antigen level \u22644.0 ng per milliliter","volume":"350","author":"Thompson","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2009.02.022_bib20","doi-asserted-by":"crossref","first-page":"441","DOI":"10.7326\/0003-4819-144-6-200603210-00012","article-title":"Viewpoint: expanding prostate cancer screening","volume":"144","author":"Catalona","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.urology.2009.02.022_bib21","author":"Ries"},{"key":"10.1016\/j.urology.2009.02.022_bib22","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0022-5347(17)35410-1","article-title":"The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer","volume":"150","author":"Partin","year":"1993","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2009.02.022_bib23","first-page":"267","article-title":"Prostate-specific antigen (PSA) best practice policy","volume":"4","year":"2000","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.urology.2009.02.022_bib24","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1056\/NEJM199608013350502","article-title":"Age-specific reference ranges for prostate-specific antigen in black men","volume":"335","author":"Morgan","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2009.02.022_bib25","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.urology.2006.09.041","article-title":"Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng\/mL","volume":"69","author":"Al-Azab","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.urology.2009.02.022_bib26","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1016\/j.ejca.2007.09.022","article-title":"Prostate volume and adverse prostate cancer features: fact not artifact","volume":"43","author":"Briganti","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urology.2009.02.022_bib27","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.urology.2007.05.017","article-title":"High yield of saturation prostate biopsy for patients with previous negative biopsies and small prostates","volume":"70","author":"Sajadi","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.urology.2009.02.022_bib28","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.eururo.2008.06.076","article-title":"PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging","volume":"54","author":"Loeb","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2009.02.022_bib29","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1002\/pros.20825","article-title":"Family history of prostate and breast cancer and the risk of prostate cancer in the PSA era","volume":"68","author":"Chen","year":"2008","journal-title":"Prostate"},{"key":"10.1016\/j.urology.2009.02.022_bib30","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1056\/NEJM200007133430201","article-title":"Environmental and heritable factors in the causation of cancer\u2014analyses of cohorts of twins from Sweden, Denmark, and Finland","volume":"343","author":"Lichtenstein","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2009.02.022_bib31","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1056\/NEJMoa075819","article-title":"Cumulative association of five genetic variants with prostate cancer","volume":"358","author":"Zheng","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2009.02.022_bib32","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/pros.20793","article-title":"Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations","volume":"68","author":"Sun","year":"2008","journal-title":"Prostate"},{"key":"10.1016\/j.urology.2009.02.022_bib33","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ng2015","article-title":"Multiple regions within 8q24 independently affect risk for prostate cancer","volume":"39","author":"Haiman","year":"2007","journal-title":"Nat Genet"},{"issue":"4 Pt. 1","key":"10.1016\/j.urology.2009.02.022_bib34","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1097\/00005392-200210010-00027","article-title":"Follow up interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels","volume":"168","author":"Lefkowitz","year":"2002","journal-title":"J Urol"},{"issue":"2 Pt. 1","key":"10.1016\/j.urology.2009.02.022_bib35","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0022-5347(01)67044-7","article-title":"Morphometric analysis and clinical follow up of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate","volume":"154","author":"Keetch","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2009.02.022_bib36","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/sj.pcan.4501026","article-title":"New circulating biomarkers for prostate cancer","volume":"11","author":"Bensalah","year":"2008","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urology.2009.02.022_bib37","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nm0495-282","article-title":"Elevated plasma levels of TGF-\u03b21 in patients with invasive prostate cancer","volume":"1","author":"Ivanovic","year":"1995","journal-title":"Nat Med"},{"key":"10.1016\/j.urology.2009.02.022_bib38","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0090-4295(96)00426-8","article-title":"Transforming growth factor beta as a clinical biomarker for prostate cancer","volume":"49","author":"Perry","year":"1997","journal-title":"Urology"},{"issue":"suppl 4A","key":"10.1016\/j.urology.2009.02.022_bib39","first-page":"2657","article-title":"Serum concentrations of transforming growth factor-\u03b21 in patients with benign and malignant prostatic diseases","volume":"19","author":"Wolff","year":"1999","journal-title":"Anticancer Res"},{"key":"10.1016\/j.urology.2009.02.022_bib40","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1038\/sj.bjc.6601814","article-title":"Serum levels of IL-6 and TNF-\u03b1 correlate with clinicopathological features and patient survival in patients with prostate cancer","volume":"90","author":"Michalaki","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urology.2009.02.022_bib41","first-page":"2702","article-title":"Serum interleukin 6 as a prognostic factor in patients with prostate cancer","volume":"6","author":"Nakashima","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urology.2009.02.022_bib42","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.juro.2008.01.013","article-title":"PCA3 molecular urine assay correlates with prostate cancer tumor volume: Implication in selecting candidates for active surveillance","volume":"179","author":"Nakanishi","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2009.02.022_bib43","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.eururo.2008.06.071","article-title":"Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy","volume":"54","author":"Haese","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2009.02.022_bib44","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1016\/j.juro.2007.07.010","article-title":"Prostate cancer risk assessment program: a 10-year update of cancer detection","volume":"178","author":"Giri","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2009.02.022_bib45","first-page":"60","article-title":"BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian","volume":"7","author":"Friedenson","year":"2005","journal-title":"MedGenMed"},{"key":"10.1016\/j.urology.2009.02.022_bib46","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1158\/1078-0432.CCR-03-0604","article-title":"BRCA mutations and risk of prostate cancer in Ashkenazi Jews","volume":"10","author":"Kirchhoff","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urology.2009.02.022_bib47","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.urology.2007.01.097","article-title":"EPCA-2: a highly specific serum marker for prostate cancer","volume":"69","author":"Leman","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.urology.2009.02.022_bib48","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S0022-5347(08)62052-2","article-title":"Analysis of a second EPCA-2 epitope as a serum test for prostate cancer (abstract)","volume":"179","author":"Leman","year":"2008","journal-title":"J Urol"}],"updated-by":[{"DOI":"10.1016\/j.urology.2010.08.003","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000}}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009042950900274X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009042950900274X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,19]],"date-time":"2019-05-19T11:01:10Z","timestamp":1558263670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009042950900274X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S009042950900274X"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2009.02.022","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.urology.2010.08.003","asserted-by":"object"}]},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}